Risperidone

證據等級: L5

預測適應症: 6 個

Risperidone: Evaluation Pending — No Repurposing Prediction Available

One-Sentence Summary

Risperidone (DB00734) is a well-known atypical antipsychotic commonly used for schizophrenia and related conditions. However, the current Evidence Pack contains no TxGNN-predicted repurposing indications, no mechanism of action data, and no safety records — making a substantive repurposing evaluation impossible at this stage. Immediate data remediation is required before this candidate can advance.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	N/A — No predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — currently not even reached)
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why No Evaluation Can Be Performed

The TxGNN prediction pipeline returned zero predicted indications for Risperidone in this Evidence Pack version (v4, data cutoff 2026-04-20). This is an upstream pipeline issue rather than a reflection of Risperidone's clinical potential.

Two blocking data gaps have been formally identified:

Gap ID	Category	Missing Item	Severity	Impact
DG001	Drug Level	Package insert warnings / contraindications	Blocking	Cannot perform S1 safety screening
DG002	Drug Level	Mechanism of action (MOA)	High	Cannot perform mechanistic relevance analysis

Until the TxGNN pipeline produces at least one predicted indication, and until DG001 is resolved, no downstream evaluation (mechanism analysis, clinical trial mapping, or safety profiling) can proceed.

Clinical Trial Evidence

Currently no related clinical trials registered for this candidate.

(Prerequisite: TxGNN predicted indication must be available before trial mapping is performed.)

Literature Evidence

Currently no related literature available.

(Prerequisite: TxGNN predicted indication must be available before literature search is performed.)

Taiwan Market Information

Risperidone has no registered licenses in the Taiwan market according to the current TFDA query (queried 2026-03-29, result count: 0).

Note: The TFDA package insert query (query ID 4) returned 1 result — this may indicate a package insert exists for reference purposes even without an active marketing authorization. The package insert should be retrieved and parsed to resolve DG001.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields — key warnings, contraindications, and drug-drug interactions — returned no data in the current Evidence Pack. DDI query status: not found.)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Risperidone (v4) is structurally incomplete — no TxGNN repurposing predictions were generated, and two high-severity data gaps (DG001, DG002) block safety screening and mechanistic analysis. There is no evaluable repurposing hypothesis at this time.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB00734 and confirm at least one predicted indication is returned
Resolve DG001 — Download and parse the TFDA package insert PDF (1 document found in query log) to extract warnings and contraindications
Resolve DG002 — Query DrugBank API for Risperidone's full mechanism of action, pharmacological class, and targets
Re-run DDI query — Current status is not_found; verify query parameters and retry
Re-generate Evidence Pack (v5+) once the above data is available, then re-submit for evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.